UCB Sues Synthon Over ANDA For Xyzal

Law360, New York (April 16, 2008, 12:00 AM EDT) -- Belgian drugmaker UCB SA and its U.S. partner, Sepracor Inc., are suing Synthon Pharmaceuticals Inc. over the company's planned generic version of the antihistamine Xyzal.

The companies filed the suit last week in Delaware federal court claiming that North Carolina-based Synthon and its Dutch parent company, Synthon Holding BV, and affiliates had infringed the patent behind levocetirizine dihydrochloride 5 mg tablets, which UCB sells under the name Xyzal.

UCB said it had received word from Synthon in late February that the company had filed an abbreviated...
To view the full article, register now.